SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Blue Owl Capital, Inc. operates as an alternative asset management firm. It provides investors access to asset management capital solutions through its Direct Lending and GP Capital Solutions products. The company offers a platform of capital solutions to both middle market companies and large alternative asset managers. The company was founded by Doug Irving Ostrover, Michael Rees and Craig W.Packer in 2009 and is headquartered in New York, NY.

Blue Owl Capital Inc - Ordinary Shares - Class A

NextDecade Corp. is a development company, which focuses on liquefied natural gas (LNG) export projects and associated pipelines. It develops and manages land-based and floating liquefied natural gas projects in the Gulf Coast with focus on the Rio Grande LNG. The company was founded by Kathleen Eishbrenner in 2010 and is headquartered in Houston, TX.

NextDecade Corporation

Discussion centers on speculation that Middle East LNG disruptions and shipping risks could strengthen demand and pricing for U.S. exporters, including NextDecades Rio Grande project. Bulls point to the projects progress and future capacity, while skeptics emphasize that NEXT has no current LNG production or revenue and still faces construction, financing, and competition risks.

Dogecoin (DOGE) is a cryptocurrency . Users are able to generate DOGE through the process of mining. Dogecoin has a current supply of 156,546,266,383.70521. The last known price of Dogecoin is 0.07588453 USD and is up 0.89 over the last 24 hours. It is currently trading on 1543 active market(s) with $1,129,852,058.92 traded over the last 24 hours. More information can be found at http://dogecoin.com/.

Dogecoin

Dogecoin is drawing attention for its choppy, weak trading and repeated difficulty holding above the eight-cent area, with traders also linking pressure to broader crypto-market declines. The conversation is split between bearish frustration over losses and calls to buy the dip or hold for a recovery.

Zebec Network (ZBCN) is a cryptocurrency launched in 2022and operates on the Solana platform. Zebec Network has a current supply of 99,998,768,617.445403. The last known price of Zebec Network is 0.00204055 USD and is down -0.09 over the last 24 hours. It is currently trading on 133 active market(s) with $10,537,951.06 traded over the last 24 hours. More information can be found at https://zebec.io/.

Zebec Network

Traders are focused on Zebecs payroll and payments expansion, including MoneyGram/Stellar links and Robinhood Chain support, as potential adoption drivers. Bullish holders are accumulating, while skeptics question whether actual usage will translate into ZBCN demand given its weak, uneven price performance.

Zoom Communications, Inc. engages in the provision of a communications and collaboration platform. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa. The company was founded by Eric S. Yuan in 2011 and is headquartered in San Jose, CA.

Zoom Communications Inc. - Ordinary Shares - Class A

Zooms Anthropic investment is drawing attention amid IPO-filing and valuation chatter, with bullish traders viewing the stake as a potential source of value. Others question whether it can offset Zooms modest core-business growth and competitive pressures; discussion also references recent earnings beats and raised full-year guidance.

LightPath Technologies, Inc. engages in the design, development, manufacture, and distribution of optical and infrared components. Its products include molded glass and assemblies, infrared molded lenses, diamond turned, conventional ground and polished ground lenses and assemblies, and collimator assemblies, which are used in applications involving light detection and ranging technology. The firm supports a range of customers in the field of industrial, laser, defense, medical, telecommunications, and instrumentation. The company was founded in1985 and is headquartered in Orlando, FL.

Lightpath Technologies, Inc. - Ordinary Shares - Class A

LightPaths order for more than 50,000 optical assemblies for defense-drone cameras is drawing attention to its counter-drone and thermal-optics business. Bulls see room for recurring demand and further defense orders, while skeptics want earnings and revenue to confirm the growth story; broad market and defense-sector weakness have also weighed on the shares.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

KTOS is drawing attention for its steep, prolonged selloff and repeated tests of key support, with traders debating whether the weakness reflects valuation concerns, insider selling and a broader defense-sector pullbackor an oversold buying opportunity. Optimists point to contract wins, growth prospects and analyst upgrades, while skeptics say positive developments have not reversed the downtrend ahead of upcoming earnings.

Cosmos (ATOM) is a cryptocurrency . Cosmos has a current supply of 538,743,080.257876. The last known price of Cosmos is 1.54934617 USD and is up 3.36 over the last 24 hours. It is currently trading on 999 active market(s) with $34,414,170.84 traded over the last 24 hours. More information can be found at https://cosmos.network/.

Cosmos

Cosmos ATOM is drawing attention amid persistent price weakness, with holders highlighting staking rewards and hoping for renewed adoption and an altcoin rebound. Bearish traders counter that token inflation and a fading ecosystem are weighing on the outlook; institutional-adoption and regulatory catalysts remain largely speculative in the discussion.

Sky (SKY) is a cryptocurrency and operates on the Ethereum platform. Sky has a current supply of 23,452,431,915.60596656 with 23,422,827,962.33348843 in circulation. The last known price of Sky is 0.06706993 USD and is up 0.91 over the last 24 hours. It is currently trading on 257 active market(s) with $49,629,100.47 traded over the last 24 hours. More information can be found at https://sky.money/.

Skycoin

Galaxy Digitals adoption of Skys yield-bearing stablecoin for its treasury and lending collateral, alongside a reported purchase of SKY, is driving discussion of growing institutional interest in the Sky ecosystem. Traders are watching for a breakout, while others see the recent pullback as a warning and question whether the rally can hold.

Direxion Shares ETF Trust - Direxion Daily GOOGL Bull 2X ETF

Direxion Daily GOOGL Bull 2X Shares ETF

Alphabets sharp post-earnings selloff is driving attention to GGLL, with many traders buying the dip for a rebound while others warn that market weakness and deteriorating technicals could bring further declines.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, November 5, 2026, following the release of its third quarter 2026 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or...

Will Nerlynx Continue to Aid Puma Biotechnology's Top Line in Q3?

PBYI raised its 2026 Nerlynx sales outlook after 3.5% first-half 2026 growth, with Q3 revenues expected to reach $54-$56 million.

The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema Oncology

AstraZeneca, Roche, Puma Biotechnology and Olema Oncology offer breast cancer treatment opportunities, with drug sales growth, pipeline advances and clinical milestones shaping prospects.

4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month

AZN, RHHBY, PBYI and OLMA offer exposure to breast cancer drug sales growth, expanded treatment approvals and clinical milestones that could shape prospects.

Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on October 1, 2026, the Compensation Committee of Pumas Board of Directors approved the grant of an inducement restricted stock unit award covering 7,500 shares of Puma common stock to one new non-executive...

PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins

Puma Biotechnology starts the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.

Puma Biotechnology Initiates ALISCA-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the initiation of its ALISertib in CAncer (ALISCA-Lung2) Phase II trial (PUMA-ALI-4202; NCT07465757) of alisertib in combination with paclitaxel for the treatment of patients with advanced small cell lung cancer. The...

Puma Biotechnology to Present at H.C. Wainwrights 28th Annual Global Investment Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 3:30 p.m. ET on Monday, September 14, at the H.C. Wainwright 28th Annual Global Investment Conference...

Axsome (AXSM) Down 3.7% Since Last Earnings Report: Can It Rebound?

Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on September 1, 2026, the Compensation Committee of Pumas Board of Directors approved the grant of inducement restricted stock unit awards covering 33,550 shares of Puma common stock to five new non-executive...

Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Puma Biotechnology Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$10.44
Prev Close	$10.54
Open	$10.56
Dividend Yield	0.00%
50-Day Moving Average	$9.82
Beta	0.79
Avg. Volume	311,258.77
PE Ratio	20.22

52-Week High	$11.50
52-Week Low	$4.58
Market Capitalization	$538.91M
EPS (Annual)	$0.6142
Price to Book	3.85
Revenue Per Employee	$1.28M

Feed

News

Sentiment

Earnings

Fundamentals

Info

PBYI Fundamentals